BlackRock
RCEL icon

BlackRock’s Avita Medical RCEL Stock Holding History

BlackRock’s Portfolio RCEL Stock Details RCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.33M Sell
564,952
-568,174
-50% -$2.45M ﹤0.01% 4123
2026
Q1 		$4.19M Buy
1,133,126
+53,427
+5% +$224K ﹤0.01% 3897
2025
Q4 		$3.72M Sell
1,079,699
-58,737
-5% -$234K ﹤0.01% 3936
2025
Q3 		$5.82M Sell
1,138,436
-757,219
-40% -$3.95M ﹤0.01% 3716
2025
Q2 		$10M Buy
1,895,655
+46,408
+3% +$338K ﹤0.01% 3421
2025
Q1 		$15.1M Sell
1,849,247
-19,356
-1% -$181K ﹤0.01% 3094
2024
Q4 		$23.9M Buy
1,868,603
+8,084
+0.4% +$95.3K ﹤0.01% 2926
2024
Q3 		$19.9M Buy
1,860,519
+76,756
+4% +$721K ﹤0.01% 3046
2024
Q2 		$14.1M Buy
1,783,763
+34,183
+2% +$325K ﹤0.01% 3180
2024
Q1 		$28M Sell
1,749,580
-56,569
-3% -$916K ﹤0.01% 2796
2023
Q4 		$24.8M Buy
1,806,149
+88,867
+5% +$1.02M ﹤0.01% 2888
2023
Q3 		$25.1M Buy
1,717,282
+46,718
+3% +$791K ﹤0.01% 2811
2023
Q2 		$28.4M Buy
1,670,564
+1,187,767
+246% +$17.4M ﹤0.01% 2812
2023
Q1 		$6.74M Buy
482,797
+6,995
+1% +$74.4K ﹤0.01% 3505
2022
Q4 		$3.14M Buy
475,802
+1,419
+0.3% +$8.5K ﹤0.01% 3936
2022
Q3 		$2.5M Sell
474,383
-2,507
-0.5% -$15.5K ﹤0.01% 4073
2022
Q2 		$2.27M Sell
476,890
-1,090,740
-70% -$6.74M ﹤0.01% 4208
2022
Q1 		$13.3M Sell
1,567,630
-20,962
-1% -$193K ﹤0.01% 3424
2021
Q4 		$19M Buy
1,588,592
+17,239
+1% +$263K ﹤0.01% 3303
2021
Q3 		$27.8M Buy
1,571,353
+3,270
+0.2% +$61.7K ﹤0.01% 3067
2021
Q2 		$32.2M Buy
1,568,083
+1,290,956
+466% +$25.4M ﹤0.01% 3002
2021
Q1 		$5.49M Buy
277,127
+126,829
+84% +$2.95M ﹤0.01% 3903
2020
Q4 		$2.79M Buy
150,298
+18,632
+14% +$409K ﹤0.01% 3927
2020
Q3 		$3.31M Buy
+131,666
New +$3.28M ﹤0.01% 3744
2020
Q1 		– Sell
-1
Closed – – 5056
2019
Q4 		$0 Buy
+1
New +$42 ﹤0.01% 5055

Other funds holding RCEL

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

BlackRock's RCEL Position: Q2 2026 in Review

BlackRock reduced its Avita Medical (RCEL) stake by 50% in Q2 2026, selling an estimated $2.45M and leaving 564,952 shares worth $2.33M. The position accounts for ﹤0.01% of the portfolio, ranked #4123.

BlackRock first reported a position in RCEL in Q4 2019 and has held it in 25 quarters since. The position peaked at $32.2M in Q2 2021. 74 funds tracked by Wall St. Rank hold RCEL as of Q2 2026.

  • BlackRock held 564,952 shares of Avita Medical worth $2.33M as of Q2 2026.
  • BlackRock sold 568,174 Avita Medical shares in Q2 2026, an estimated $2.45M.
  • Avita Medical made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4123 holding.
  • BlackRock first reported a position in Avita Medical in Q4 2019 and has held it in 25 quarters since.
  • BlackRock's Avita Medical position peaked at $32.2M in Q2 2021.
  • 74 funds tracked by Wall St. Rank held Avita Medical as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.